Resolving Early Targets and Metabolomic Profile of Congenital Heart Disease Through Tandem Mass Spectrometry Screening in Neonates
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.039500 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Jiayu Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Heart Center Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health Hangzhou China. Hauptthemen laut MEDLINE: Heart Defects, Congenital, Tandem Mass Spectrometry, Metabolomics, Neonatal Screening. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
A good prognosis of congenital heart disease (CHD) depends on early diagnosis and intervention. Under the current screening conditions, a significant proportion still go undetected. Metabolomics, as a phenotype‐correlated research methodology, remains underused in the study of CHD, which could provide the possibility to screen neonatal CHD efficiently.
Methods
Data for the analysis are from >22 000 neonates captured in the Network Platform for CHD from April 2020 to November 2021 in 11 cities in China. After data matching and quality control, a total of 22 674 neonates were finally included and divided into the CHD group (n=1823), nonsignificant CHD group (n=17 968), and normal group (n=2748). Demographic and clinical characteristics and tandem mass spectrometry‐based metabolic data for genetic and metabolic disease screening were gathered and compared for all groups. Machine learning models based on metabolic biomarkers were constructed to screen CHD in neonates.
Results
After quality control, 22 539 neonates were ultimately included. Among them, 1823 were diagnosed with CHD, 17 968 were nonsignificant CHD, and 2748 were normal. A total of 46 distinguishing metabolic biomarkers were identified, and we found that the CHD group had significantly lower levels of 17‐hydroxyprogesterone (CHD versus nonsignificant CHD, P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heart Center Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health Hangzhou China.
- Binjiang Institute of Zhejiang University Hangzhou China.
- Department of Genetics and Metabolism Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health Hangzhou China.
ORCID-Profile: Jiayu Zhang, Wei Jiang, Die Li, Weijie Jia, Dingfeng Wu, Weize Xu, Qiang Shu
Zitieren
APA
Zhang, J., Jiang, W., Li, D., Jia, W., Wu, D., Yang, R., Xu, W., & Shu, Q. (2025). Resolving Early Targets and Metabolomic Profile of Congenital Heart Disease Through Tandem Mass Spectrometry Screening in Neonates. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.039500
Vancouver
Zhang J, Jiang W, Li D, Jia W, Wu D, Yang R, et al. Resolving Early Targets and Metabolomic Profile of Congenital Heart Disease Through Tandem Mass Spectrometry Screening in Neonates. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.039500
BibTeX
@article{Zhang2025,
author = {Zhang, Jiayu and Jiang, Wei and Li, Die and Jia, Weijie and Wu, Dingfeng and Yang, Rulai and Xu, Weize and Shu, Qiang},
title = {Resolving Early Targets and Metabolomic Profile of Congenital Heart Disease Through Tandem Mass Spectrometry Screening in Neonates},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.039500}
}
EUVIMED